Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Poised To File Isatuximab In Multiple Myeloma, Going Up Against J&J's Darzalex

05 Feb 2019

• By Jessica Merrill

Open Book Of prostate multiple myeloma, Conceptual Image - Image

Related Content

Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche

24 Apr 2018

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

29 Sep 2018

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

11 Sep 2018

Darzalex Excites As Potential Grows In Multiple Myeloma

30 Oct 2018

Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma

17 Nov 2015

This Isn't The Big One: Darzalex Wins US Approval In First-Line Multiple Myeloma

08 May 2018

Related Companies

Sanofi

Johnson & Johnson

Genmab A/S

Bristol Myers Squibb Company

Takeda Pharmaceutical Co. Ltd.

Regeneron Pharmaceuticals, Inc.

Roche Holding AG

Additional Topics

Research & Development Business Strategies Cancer BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.